Form 4: David J. Matlin Acquires Stock Options in TriSalus Life Sciences

Director David J. Matlin reports acquisition of stock options in TriSalus Life Sciences, Inc.

Summary

• David J. Matlin, a director of TriSalus Life Sciences, Inc. (TLSI), reported the acquisition of stock options.
• The transaction occurred on August 13, 2024.
• Matlin acquired options to purchase 15,000 shares of common stock at an exercise price of $5.75.
• The options vest fully on the one-year anniversary of the grant date or at the next annual stockholder meeting, contingent upon continued service.
• Following the transaction, Matlin directly owns options for 15,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, indicating continued alignment with the company's interests but not necessarily a strong positive or negative signal.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule tied to continued service suggests an expectation of ongoing involvement by the director.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates a director's continued investment in the company's success.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates